Key result
Low skeletal muscle mass is linked to ~2.3-fold higher risk of anthracycline-related cardiotoxicity.
Why the study?
Sarcopenia may increase vulnerability to anthracycline-related cardiac toxicity in adult cancer patients, but evidence regarding this association remained limited.
Does sarcopenia or low skeletal muscle mass increase the risk of anthracycline-related cardiac toxicity in adult cancer patients receiving anthracycline-based chemotherapy?
Meta-Analysis (n=742)
Does sarcopenia or low skeletal muscle mass increase the risk of anthracycline-related cardiac toxicity in adult cancer patients receiving anthracycline-based chemotherapy?
In adult cancer patients receiving anthracyclines, baseline low skeletal muscle mass is associated with a more than twofold increased risk of anthracycline-related cardiotoxicity, suggesting muscle assessment may aid in cardio-oncology risk stratification.
Answers are grounded in this paper and cite their sources.
May support muscle assessment in anthracycline cardiotoxicity risk stratification; leaves open prospective validation before practice change.
Introduction. Sarcopenia may increase vulnerability to anthracycline-related cardiac toxicity (ARCT), but evidence remains limited. We evaluated whether sarcopenia or low skeletal muscle mass is associated with ARCT in adult cancer patients. Material and methods. A systematic review and meta-analysis was performed in accordance with the PRISMA 2020 and MOOSE guidelines. PubMed, Scopus, Google Scholar, and Cochrane-CENTRAL were searched through May 2026. Eligible studies enrolled adults receiving predominantly anthracycline-based chemotherapy with objective muscle assessment and cardiac or cardiorespiratory outcomes. Estimates reported as hazard ratios (HRs) were pooled using a random-effects model. Results. Five studies were included (n = 742); two cohorts (n = 491) were eligible for meta-analysis. Sarcopenia prevalence ranged from 10.2% to 27.1%. Low skeletal muscle mass was associated with a higher risk of ARCT [hazard ratio (HR) = 2.31, Wald 95% confidence interval (CI) 1.07–5.00; p = 0.034; I² = 60%; τ² = 0.19]. Some qualitative evidence also linked lower muscle mass or poorer muscle quality with greater cardiac functional decline. Conclusions. Baseline muscle assessment may help identify patients at increased risk of ARCT. These exploratory findings require validation before guiding cardio-oncology surveillance.
No takes yet. Share an insight, caveat, or question.
Alijew et al. (2026) conducted a meta-analysis in Adult cancer patients receiving predominantly anthracycline-based chemotherapy (n=742). Sarcopenia or low skeletal muscle mass vs. Normal skeletal muscle mass / absence of sarcopenia was evaluated on Anthracycline-related cardiac toxicity (ARCT) (HR 2.31, 95% CI 1.07-5.00, p=0.034). Low skeletal muscle mass was associated with a higher risk of anthracycline-related cardiotoxicity in adult cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: